

Financial news for NVRO dated on 2020-06-08: Benzinga's Top Upgrades, Downgrades For June 8, 2020

Financial news for NVRO dated on 2020-06-08: 10 Biggest Price Target Changes For Monday

Financial news for NVRO dated on 2020-06-08: UBS Upgrades Nevro to Neutral, Raises Price Target to \$132

Financial news for NVRO dated on 2020-06-04: Nevro Appoints Finance Executive Roderick MacLeod As Chief Financial Officer

Financial news for NVRO dated on 2020-05-14: Nevro Reports CE Mark Approval Of Senza Omnia Spinal Cord Stimulation System To Treat Chronic Pain

Financial news for NVRO dated on 2020-05-06: SunTrust Robinson Humphrey Maintains Buy on Nevro, Raises Price Target of \$135

Financial news for NVRO dated on 2020-05-06: JP Morgan Maintains Neutral on Nevro, Raises Price Target to \$100

Financial news for NVRO dated on 2020-05-06: Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to \$135

Financial news for NVRO dated on 2020-05-05: Nevro Q1 EPS \$(0.780) Beats \$(0.970) Estimate, Sales \$87.467M Miss \$89.460M Estimate

Financial news for NVRO dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for NVRO dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for NVRO dated on 2020-04-09: Nevro Reports Federal Circuit Rules In Its Favor, Upholds Validity Of Co.'s Patent Claims In Litigation Against Boston Scientific

Financial news for NVRO dated on 2020-04-03: Morgan Stanley Maintains Overweight on Nevro, Lowers Price Target to \$113

Financial news for NVRO dated on 2020-04-02: JP Morgan Maintains Neutral on Nevro, Lowers Price Target to \$90

Financial news for NVRO dated on 2020-04-02: Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to \$114

Financial news for NVRO dated on 2020-04-02: SunTrust Robinson Humphrey Maintains Buy on Nevro, Lowers Price Target to \$120

Financial news for NVRO dated on 2020-04-02: Wells Fargo Maintains Overweight on Nevro, Lowers Price Target to \$126

Financial news for NVRO dated on 2020-04-02: Nevro shares are trading lower after the company announced a common stock offering of 1.6 million shares at \$84 per share. UPDATE: Shares have since reversed, now higher.

Financial news for NVRO dated on 2020-04-02: Nevro Corp Announces Pricing Concurrent Offering Of 1.6M Shares Of Its Common Stock At A Public Offering Price Of \$84/Share

Financial news for NVRO dated on 2020-04-02: The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affirmed Granted Orphan Drug Designation

Financial news for NVRO dated on 2020-04-01: Nevro Announces 1.625M Common Stock Offering

Financial news for NVRO dated on 2020-04-01: Nevro Sees Prelim. Q1 Sales \$86.4M-\$86.9M vs \$96.96M Est.; Says As Of Dec. 31 Had \$238M In Cash And Equivalents

Financial news for NVRO dated on 2020-03-27: Morgan Stanley Maintains Overweight on Nevro, Lowers Price Target to \$118

Financial news for NVRO dated on 2020-03-27: Citigroup Maintains Buy on Nevro, Lowers Price Target to \$130

Financial news for NVRO dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus

measures to support liquidity.

Financial news for NVRO dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lilly, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for NVRO dated on 2020-02-26: 75 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NVRO dated on 2020-02-26: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVRO dated on 2020-02-26: Benzinga's Top Upgrades, Downgrades For February 26, 2020

Financial news for NVRO dated on 2020-02-26: Wells Fargo Maintains Overweight on Nevro, Raises Price Target to \$158

Financial news for NVRO dated on 2020-02-26: JP Morgan Maintains Neutral on Nevro, Raises Price Target to \$130

Financial news for NVRO dated on 2020-02-26: Canaccord Genuity Upgrades Nevro to Buy, Raises Price Target to \$153

Financial news for NVRO dated on 2020-02-25: Nevro Reaffirms FY20 Sales Guidance Of \$435M-\$440M vs \$437.06M Est.

Financial news for NVRO dated on 2020-02-25: Nevro Q4 EPS \$(0.44) Beats \$(0.62) Estimate, Sales \$114.4M Beat \$111.8M Estimate

Financial news for NVRO dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for NVRO dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for NVRO dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for NVRO dated on 2020-02-19: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVRO dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for NVRO dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for NVRO dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for NVRO dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for NVRO dated on 2020-01-29: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVRO dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for NVRO dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for NVRO dated on 2020-01-27: 27 Medical Devices Stocks Moving In Monday's Session

Financial news for NVRO dated on 2020-01-27: Stocks That Hit 52-Week Highs On Monday

Financial news for NVRO dated on 2020-01-27: Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to \$142

Financial news for NVRO dated on 2020-01-27: 10 Biggest Price Target Changes For Monday

Financial news for NVRO dated on 2020-01-27: JMP Securities Maintains Market Outperform on Nevro, Raises Price Target to \$150

Financial news for NVRO dated on 2020-01-24: The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

Financial news for NVRO dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for NVRO dated on 2020-01-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVRO dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for NVRO dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for NVRO dated on 2020-01-15: UBS Maintains Sell on Nevro, Raises Price Target to \$84

Financial news for NVRO dated on 2020-01-14: Nevro Sees Prelim. Q4 Sales \$114.4M vs \$109.73M Est., Prelim. FY19 Sales \$390.3M vs \$385.65M Est.; Sees FY20 Sales \$435M-\$440M vs \$433.08M Est.

Financial news for NVRO dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for NVRO dated on 2020-01-08: Benzinga's Top Upgrades, Downgrades For January 8, 2020

Financial news for NVRO dated on 2020-01-08: SunTrust Robinson Humphrey Initiates Coverage On Nevro with Buy Rating, Announces \$132 Price Target

Financial news for NVRO dated on 2020-01-07: The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

Financial news for NVRO dated on 2020-01-06: Oppenheimer Downgrades Nevro to Perform

Financial news for NVRO dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for NVRO dated on 2020-01-02: The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

Financial news for NVRO dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for NVRO dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for NVRO dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for NVRO dated on 2019-12-20: JP Morgan Maintains Neutral on Nevro, Raises Price Target to \$96

Financial news for NVRO dated on 2019-12-17: Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to \$125

Financial news for NVRO dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for NVRO dated on 2019-11-27: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVRO dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for NVRO dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for NVRO dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Collectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for NVRO dated on 2019-11-20: Stocks That Hit 52-Week Highs On

Wednesday

Financial news for NVRO dated on 2019-11-08: UBS Maintains Sell on Nevro, Raises Price Target to \$77

Financial news for NVRO dated on 2019-11-08: 94 Biggest Movers From Yesterday

Financial news for NVRO dated on 2019-11-07: 75 Stocks Moving In Thursday's Mid-Day Session

Financial news for NVRO dated on 2019-11-07: Canaccord Genuity Maintains Hold on Nevro, Raises Price Target to \$88

Financial news for NVRO dated on 2019-11-07: Stocks That Hit 52-Week Highs On Thursday

Financial news for NVRO dated on 2019-11-07: Benzinga's Top Upgrades, Downgrades For November 7, 2019

Financial news for NVRO dated on 2019-11-07: Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to \$100

Financial news for NVRO dated on 2019-11-07: JP Morgan Maintains Neutral on Nevro, Raises Price Target to \$80

Financial news for NVRO dated on 2019-11-07: Wells Fargo Maintains Outperform on Nevro, Raises Price Target to \$105

Financial news for NVRO dated on 2019-11-07: Oppenheimer Upgrades Nevro to Outperform, Announces \$106 Price Target

Financial news for NVRO dated on 2019-11-06: Nevro Raises FY19 Sales Guidance From \$368M-\$374M To \$484M-\$386M vs \$373.19M Est.

Financial news for NVRO dated on 2019-11-06: Nevro Q3 EPS \$(0.58) Beats \$(0.86) Estimate, Sales \$100.2M Beat \$92.8M Estimate

Financial news for NVRO dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for NVRO dated on 2019-11-05: Nevro Recieves FDA Approval For Senza(r) Omnia(tm) Spinal Cord Stimulation System to Treat Chronic Pain

Financial news for NVRO dated on 2019-11-05: Nevro Announces US Launch Of Senza Omnia Spinal Cord Stimulation System To Treat Chronic Pain

Financial news for NVRO dated on 2019-10-22: Oppenheimer Initiates Coverage On Nevro with Perform Rating

Financial news for NVRO dated on 2019-10-09: Wells Fargo Maintains Outperform on Nevro, Raises Price Target to \$86

Financial news for NVRO dated on 2019-09-13: The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

Financial news for NVRO dated on 2019-09-12: The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study

Financial news for NVRO dated on 2019-08-28: Nevro Announces Completion Of Patient Enrollment In Multicenter Randomized Controlled Trial Of High Frequency Spinal Cord Stimulation For Painful Diabetic Neuropathy

Financial news for NVRO dated on 2019-08-26: Hearing Pacific Square Made Cautious Comments On Nevro, Unconfirmed

Financial news for NVRO dated on 2019-08-22: Stocks That Hit 52-Week Highs On Thursday

Financial news for NVRO dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for NVRO dated on 2019-08-21: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVRO dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for NVRO dated on 2019-08-12: 10 Biggest Price Target Changes For Monday

Financial news for NVRO dated on 2019-08-12: JMP Securities Reiterates Market Outperform on Nevro, Raises Price Target to \$90

Financial news for NVRO dated on 2019-08-12: 90 Biggest Movers From Friday

Financial news for NVRO dated on 2019-08-09: 75 Stocks Moving In Friday's Mid-Day Session

Financial news for NVRO dated on 2019-08-09: A List Of Stocks Reaching New 52-Week Highs

Financial news for NVRO dated on 2019-08-09: Nevro Shares Spike 17% Higher at the Open; Co Reported Narrower than Expected Loss on Thursday

Financial news for NVRO dated on 2019-08-09: Canaccord Genuity Maintains Hold on Nevro, Raises Price Target to \$59

Financial news for NVRO dated on 2019-08-08: Nevro Guides FY19 Revenues Of \$368M-\$374M Vs. \$366.97M Estimate

Financial news for NVRO dated on 2019-08-08: Nevro Q2 EPS \$(0.91) Beats \$(0.97) Estimate, Sales \$93.571M Beat \$88.4M Estimate

Financial news for NVRO dated on 2019-07-25: Nevro Announces Court Order Granting Preliminary Injunction Against Stimwave Technologies, Inc.

Financial news for NVRO dated on 2019-05-20: Nevro Names Pres, CEO Keith Grossman Chair

Financial news for NVRO dated on 2019-05-13: 72 Biggest Movers From Friday

Financial news for NVRO dated on 2019-05-10: 62 Stocks Moving In Friday's Mid-Day Session

Financial news for NVRO dated on 2019-05-10: Nevro shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results. The company also issued Q2 sales guidance below analyst estimates. Canaccord Genuity downgraded the stock from Buy to Hold.

Financial news for NVRO dated on 2019-05-10: 10 Biggest Price Target Changes For Friday

Financial news for NVRO dated on 2019-05-10: Benzinga's Top Upgrades, Downgrades For May 10, 2019

Financial news for NVRO dated on 2019-05-10: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for NVRO dated on 2019-05-10: Morgan Stanley Maintains Overweight on Nevro Corp. Common Stock, Lowers Price Target to \$64

Financial news for NVRO dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for NVRO dated on 2019-05-10: Canaccord Genuity Downgrades Nevro Corp. Common Stock to Hold, Lowers Price Target to \$50

Financial news for NVRO dated on 2019-05-10: JMP Securities Maintains Market Outperform on Nevro Corp. Common Stock, Lowers Price Target to \$70

Financial news for NVRO dated on 2019-05-09: Nevro shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results; the company also issued Q2 sales guidance below analyst estimates.

Financial news for NVRO dated on 2019-05-09: Nevro Sees Q2 Sales \$87M-\$89M vs \$99.49M

Financial news for NVRO dated on 2019-05-09: Nevro Corp. Q1 EPS \$(1.45) Misses \$(0.67) Estimate, Sales \$82.15M Miss \$87.49M Estimate

Financial news for NVRO dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for NVRO dated on 2019-04-17: Shares of several medical device companies are trading lower with the healthcare sector. Healthcare has seen weakness recently due to concerns over the future of the Affordable Act under Trump and

healthcare policy uncertainty ahead of the 2020 election.

Financial news for NVRO dated on 2019-03-21: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Thurs., Mar. 21, 2019

Financial news for NVRO dated on 2019-03-21: 5 Biggest Price Target Changes For Thursday

Financial news for NVRO dated on 2019-03-21: Benzinga's Top Upgrades, Downgrades For March 21, 2019

Financial news for NVRO dated on 2019-03-21: Morgan Stanley Upgrades Nevro to Overweight, Raises Price Target to \$70

Financial news for NVRO dated on 2019-03-21: 52 Biggest Movers From Yesterday

Financial news for NVRO dated on 2019-03-20: Mid-Afternoon Market Update: Fed Expects No Interest Rate Hikes In 2019; Dow Down Over 100 Points

Financial news for NVRO dated on 2019-03-20: Nevro's C-Suite, Board Changes Should 'Mark The Turnaround Of The Organization,' BMO Says In Upgrade

Financial news for NVRO dated on 2019-03-20: UPDATE: Bank Of America Upgrades Nevro, Raises Target From \$50 To \$70 As Firm Views New CEO Keith Grossman As 'arguably the best SMid cap commercial turn-around CEO in MedTech'

Financial news for NVRO dated on 2019-03-20: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NVRO dated on 2019-03-20: Mid-Day Market Update: Westport Fuel Systems Falls Following Downbeat Q4 Results; Nevro Shares Surge

Financial news for NVRO dated on 2019-03-20: Mid-Morning Market Update: Markets Open Lower; General Mills Earnings Top Estimates

Financial news for NVRO dated on 2019-03-20: 10 Biggest Price Target Changes For Wednesday

Financial news for NVRO dated on 2019-03-20: Wells Fargo Upgrades Nevro to Outperform

Financial news for NVRO dated on 2019-03-20: Benzinga's Top Upgrades, Downgrades For March 20, 2019

Financial news for NVRO dated on 2019-03-20: Nevro shares are trading higher after the company announced it reached a management agreement with hedge fund Broadfin Capital and two banks upgraded their recommendations of the stock.

Financial news for NVRO dated on 2019-03-20: The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

Financial news for NVRO dated on 2019-03-20: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVRO dated on 2019-03-20: BMO Capital Upgrades Nevro to Outperform, Raises Price Target to \$67

Financial news for NVRO dated on 2019-03-20: Bank of America Upgrades Nevro to Buy, Raises Price Target to \$70

Financial news for NVRO dated on 2019-03-19: Nevro Names D. Keith Grossman President And CEO

Financial news for NVRO dated on 2019-03-11: Nevro Option Alert: Apr 18 \$50 Calls at the Ask: 770 @ \$1.351 vs 33 OI; Earnings 5/6 After Close [est] Ref=\$44.43

Financial news for NVRO dated on 2019-02-25: 71 Biggest Movers From Friday

Financial news for NVRO dated on 2019-02-21: Nevro Sees FY19 Sales \$400M-\$410M vs \$419.3M Estimate

Financial news for NVRO dated on 2019-02-21: Nevro Corp. Common Stock Q4 EPS \$(0.32) Misses \$(0.21) Estimate, Sales \$107.944M Beat \$107.1M Estimate

Financial news for NVRO dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for NVRO dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for NVRO dated on 2019-02-15: Nevro Files Lawsuit For Patent Infringement Against Stimwave In The US

Financial news for NVRO dated on 2019-01-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVRO dated on 2019-01-07: Nevro Sees FY2018 Sales \$386.90M-387.40M vs \$385.46M Est

Financial news for NVRO dated on 2019-01-07: Nevro Sees Q4 Sales \$107.60M-108.10M vs \$106.15M Est

Financial news for NVRO dated on 2018-11-28: UBS Initiates Coverage On Nevro with Sell Rating, Announces \$35 Price Target

Financial news for NVRO dated on 2018-11-07: Bank Of America On Nevro: Cannot Recommend NVRO 'on the hope that strategic value is realized alone'

Financial news for NVRO dated on 2018-11-07: Bank of America Downgrades Nevro to Neutral

Financial news for NVRO dated on 2018-11-07: 75 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-11-06: Morgan Stanley Downgrades Nevro to Underweight, Lowers Price Target to \$43

Financial news for NVRO dated on 2018-11-06: 7 Biggest Price Target Changes For Tuesday

Financial news for NVRO dated on 2018-11-06: Wells Fargo Maintains Market Perform on Nevro, Lowers Price Target to \$50

Financial news for NVRO dated on 2018-11-06: Benzinga's Top Upgrades, Downgrades For November 6, 2018

Financial news for NVRO dated on 2018-11-06: JP Morgan Downgrades Nevro to Neutral, Lowers Price Target to \$45

Financial news for NVRO dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for NVRO dated on 2018-11-05: Nevro Corp. Sees FY18 Sales At Lower End Of Guidance Range Of \$385M-\$390M vs \$385.81M Est.

Financial news for NVRO dated on 2018-11-05: Nevro Corp. Common Stock Q3 EPS \$(0.37) Misses \$(0.29) Estimate, Sales \$95.63M Beat \$94.28M Estimate

Financial news for NVRO dated on 2018-10-19: 10 Biggest Price Target Changes For Friday

Financial news for NVRO dated on 2018-10-19: Benzinga's Top Upgrades, Downgrades For October 19, 2018

Financial news for NVRO dated on 2018-10-19: Goldman Sachs Downgrades Nevro to Sell, Lowers Price Target to \$44

Financial news for NVRO dated on 2018-08-09: 40 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVRO dated on 2018-08-02: Nevro Sees FY18 Sales \$385M-\$390M vs \$386.88M Est.

Financial news for NVRO dated on 2018-08-02: Nevro Corp. Common Stock Q2 EPS \$(0.35) Misses \$(0.31) Estimate, Sales \$96.08M Beat \$95.31M Estimate

Financial news for NVRO dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for NVRO dated on 2018-07-30: Nevro Reports Co., Boston Scientific Have Filed To Dismiss Remaining Claims; Boston Scientific Represents It Has No Plans to Launch High Frequency Products

Financial news for NVRO dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for NVRO dated on 2018-07-26: 50 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-07-25: Buying The Dip In Nevro Pays Off For

## Investors After Court Ruling

Financial news for NVRO dated on 2018-07-25: Mid-Afternoon Market Update: U.S. Stocks Turn Higher; Travelzoo Shares Slide

Financial news for NVRO dated on 2018-07-25: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NVRO dated on 2018-07-25: Mid-Day Market Update: Crude Oil Up Over 1%; Agile Therapeutics Shares Plunge

Financial news for NVRO dated on 2018-07-25: Stocks Which Set New 52-Week Lows Yesterday, July 24th:

Financial news for NVRO dated on 2018-07-25: Mid-Morning Market Update: Markets Mostly Lower; Coca-Cola Tops Q2 Views

Financial news for NVRO dated on 2018-07-25: Benzinga Pro's 5 Stocks To Watch Today

Financial news for NVRO dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for NVRO dated on 2018-07-25: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVRO dated on 2018-07-25: 46 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-07-25: Nevro Announces Patent Litigation Update; Says Court Found that Boston Scientific is Not Currently Infringing Six Upheld Method Claims

Financial news for NVRO dated on 2018-07-24: 7 Stocks Moving In Tuesday's After-Hours Session

Financial news for NVRO dated on 2018-07-24: UPDATE: US District Court Doc Related To Boston Scientific, Nevro Shows 'Motions To Strike Filed By Both Parties Are Denied As Moot'

Financial news for NVRO dated on 2018-07-24: Nevro Shares Now Down 28%; Traders Circulating Doc From US District Judge Showing Conference Scheduled For Aug. 2 To Confirm 'No Live Claims Remain...Judgment Can Be Entered In Full For Boston Scientific'

Financial news for NVRO dated on 2018-07-24: Downside In Nevro Shares Intensifies As \$50 Support Level Breaks; Stock Now Down ~37.4% To Below \$40

Financial news for NVRO dated on 2018-07-24: UPDATE: Nevro Shares Fall Below \$60 For First Time Since Early 2016; Not Seeing News To Justify Mid-Day Dip Below That Support Level

Financial news for NVRO dated on 2018-07-24: Nevro Shares Fall Below \$60 Level, Down ~9% Over Last Min.

Financial news for NVRO dated on 2018-07-19: Leerink Swann Maintains Outperform on Nevro, Lowers Price Target to \$90

Financial news for NVRO dated on 2018-07-17: Wells Fargo Maintains Market Perform on Nevro, Lowers Price Target to \$62

Financial news for NVRO dated on 2018-07-17: Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to \$65

Financial news for NVRO dated on 2018-07-16: Hearing Leerink Cut Nevro Corp Price Target From \$95 To \$90

Financial news for NVRO dated on 2018-07-16: Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to \$83

Financial news for NVRO dated on 2018-07-16: Nevro Raises FY2018 Sales Guidance from \$385.0M-390.0M to \$400.0M-410.0M vs \$403.13M Est

Financial news for NVRO dated on 2018-07-16: Nevro Sees Q2 Sales \$96.10M vs \$95.44M Est

Financial news for NVRO dated on 2018-07-16: 38 Biggest Movers From Friday

Financial news for NVRO dated on 2018-07-13: 30 Stocks Moving In Friday's Mid-Day Session



Financial news for NVRO dated on 2018-07-13: Nevro Shares Down 14.3% Following An 8-K From The Co. Earlier Today Announcing The Decision To Terminate James Alecxih's Employment As VP Of Worldwide Sales

Financial news for NVRO dated on 2018-07-11: Nevro Shares Close Up 4.9% After Receiving Positive Mention From Canaccord Genuity, Which Noted A Favorable Risk Reward Setup In The Shares After Tuesday's Sell-Off

Financial news for NVRO dated on 2018-07-11: 41 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-07-10: Nevro Shares Down 16.2%; Price Action May Or May Not Be Related To Traders Passing Media Report Out Yesterday Highlighting Action Last Week In The Co.'s Patent Suit With Boston Scientific

Financial news for NVRO dated on 2018-07-03: 44 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-07-02: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for NVRO dated on 2018-07-02: 3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley

Financial news for NVRO dated on 2018-07-02: Benzinga's Top Upgrades, Downgrades For July 2, 2018

Financial news for NVRO dated on 2018-07-02: Morgan Stanley Downgrades Nevro to Equal-Weight

Financial news for NVRO dated on 2018-05-09: 53 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-05-08: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NVRO dated on 2018-05-08: Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report

Financial news for NVRO dated on 2018-05-08: Mid-Morning Market Update: Markets Edge Lower; DISH Network Revenue Misses Expectations

Financial news for NVRO dated on 2018-05-08: Canaccord Genuity Maintains Buy on Nevro, Lowers Price Target to \$102

Financial news for NVRO dated on 2018-05-08: Benzinga's Top Upgrades, Downgrades For May 8, 2018

Financial news for NVRO dated on 2018-05-08: Northland Securities Downgrades Nevro to Market Perform

Financial news for NVRO dated on 2018-05-08: JMP Securities Maintains Market Outperform on Nevro, Lowers Price Target to \$105

Financial news for NVRO dated on 2018-05-08: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVRO dated on 2018-05-08: Wells Fargo Downgrades Nevro to Market Perform

Financial news for NVRO dated on 2018-05-07: Nevro Corp Shares Down 15.8% After Hours Following Q1 Miss

Financial news for NVRO dated on 2018-05-07: 9 Stocks Moving In Monday's After-Hours Session

Financial news for NVRO dated on 2018-05-07: Nevro Reaffirms FY2018 Sales Guidance \$400.0M-410.0M vs \$406.0M Est

Financial news for NVRO dated on 2018-05-07: Nevro Corp. Common Stock Q1 EPS \$(0.59) Misses \$(0.30) Estimate, Sales \$87.635M Miss \$89.47M Estimate

Financial news for NVRO dated on 2018-04-04: Goldman Sachs Initiates Coverage On Nevro with Neutral Rating, Announces \$83.00 Price Target

Financial news for NVRO dated on 2018-02-22: Nevro Reports Q4 EPS \$(0.15) vs. \$(0.14) Est., Sales \$97.96M vs. \$95.34M Est.

Financial news for NVRO dated on 2018-01-09: 48 Biggest Movers From Yesterday

Financial news for NVRO dated on 2018-01-08: Mid-Afternoon Market Update: NASDAQ Gains 0.2%; GoPro Shares Spike Higher

Financial news for NVRO dated on 2018-01-08: Nevro Shares Up 16.26%; Ealrier Co. Reported Receipt Of FDA Approval For Senza II System

Financial news for NVRO dated on 2018-01-08: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for NVRO dated on 2018-01-08: Mid-Day Market Update: Dave & Buster's Drops On Lowered Outlook; Nevro Shares Surge

Financial news for NVRO dated on 2018-01-08: Nevro Sees Q4 Sales \$97.4M-\$97.9M vs \$90.4M Est.; Sees FY17 Sales \$326.1M-\$326.6M vs \$319M Est.

Financial news for NVRO dated on 2017-11-06: Nevro Narrows FY17 Sales From \$310-\$320M To \$315-\$320M

Financial news for NVRO dated on 2017-11-06: Nevro Reports Q3 EPS \$(0.21) vs \$(0.22) Est., Sales \$82.2M vs \$80.4M Est.

Financial news for NVRO dated on 2017-08-07: Nevro Sees FY17 Sales \$310M-\$320M vs \$316.95M Est.

Financial news for NVRO dated on 2017-08-07: Nevro Reports Q2 EPS \$(0.40) vs \$(0.30) Est., Sales \$78.016M vs \$74.96M Est.

Financial news for NVRO dated on 2017-07-05: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for NVRO dated on 2017-07-05: Mid-Day Market Update: NASDAQ Turns Positive; O'Reilly Shares Drop Following Disappointing Comparable Store Sales

Financial news for NVRO dated on 2017-07-05: Nevro Corp Shares Moving 10% Higher After Reporting A Strong Q2 Sales Forecast

Financial news for NVRO dated on 2017-07-05: Mid-Morning Market Update: Markets Drop; Vantiv To Acquire Worldpay

Financial news for NVRO dated on 2017-07-05: Nevro Sees FY Sales \$310M to \$320M vs \$316M Est

Financial news for NVRO dated on 2017-07-05: Nevro Sees Q2 Sales \$77.5M to \$78.0M vs \$74.1M Est

Financial news for NVRO dated on 2017-05-09: 20 Biggest Mid-Day Losers For Tuesday

Financial news for NVRO dated on 2017-05-09: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVRO dated on 2017-05-09: B. Riley Downgrades Nevro to Neutral

Financial news for NVRO dated on 2017-05-08: Nevro Reports Q1 EPS \$(0.50) May Not Compare To \$(0.25) Est., Sales \$68.439M vs \$68.71M Est.

Financial news for NVRO dated on 2017-02-23: Nevro Reports Q4 EPS \$(0.34) vs \$(0.20) Est., Sales \$70.5M vs \$66.41M Est.

Financial news for NVRO dated on 2016-12-09: Boston Scientific Files Patent Lawsuit Against Nevro

Financial news for NVRO dated on 2016-11-21: 8-K from Nevro Shows Co. Entered Multi-Year Supply Deal with Centro de Construcccion de Cardioestimuladores del uruguay

Financial news for NVRO dated on 2016-11-08: 18 Biggest Mid-Day Losers For Tuesday

Financial news for NVRO dated on 2016-11-08: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVRO dated on 2016-11-07: UPDATE: Nevro Raises FY16 Revenue Guidance From \$210M-\$220M To \$220M-\$225M vs \$222.22M Est

Financial news for NVRO dated on 2016-11-07: Nevro Reports Q3 Loss/Share \$0.14 vs Est Loss/Share \$0.40, Rev \$60.9M vs \$58.05M Est

Financial news for NVRO dated on 2016-11-07: Nevro Raises FY16 Revenue Guidance

Financial news for NVRO dated on 2016-09-26: Nevro Spikes to High of \$104.14 on Volume

Financial news for NVRO dated on 2016-09-16: B. Riley Initiates Coverage on Nevro at Buy, Announces \$114.00 PT

Financial news for NVRO dated on 2016-09-06: Nevro Corp. Reports SENZA-RCT Results Show Sustained Superiority Of HF10 Over Traditional Spinal Cord Stimulation For Chronic Pain Across All Primary & Secondary Endpoints

Financial news for NVRO dated on 2016-08-09: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for NVRO dated on 2016-08-09: Benzinga's Volume Movers

Financial news for NVRO dated on 2016-08-09: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVRO dated on 2016-08-08: After-Hours Gainers Aug. 8, 2016: HIIQ Up 36%, REN 20%, CCXI 14.4%, FH 14.3%, FGEN 10.4%, AMPH 9.4%, CSLT 8.9%, NVRO 8.7%, ENDP 7.5%

Financial news for NVRO dated on 2016-08-08: Nevro updates FY 16 guidance

Financial news for NVRO dated on 2016-08-08: Nevro Reports Q2 Loss/Share (\$0.31) vs Est Loss/Share (\$0.47), Rev \$55.4M vs \$45.11M Est

Financial news for NVRO dated on 2016-08-08: Nevro Initiated With Buy Rating At Bank Of America

Financial news for NVRO dated on 2016-08-08: Benzinga's Top Initiations

Financial news for NVRO dated on 2016-08-08: Bank of America Initiates Coverage on Nevro at Buy

Financial news for NVRO dated on 2016-07-22: Benzinga's Top Initiations

Financial news for NVRO dated on 2016-07-22: The Market In 5 Minutes: The Dow's Win Streak Comes To An End

Financial news for NVRO dated on 2016-07-22: PiperJaffray Initiates Coverage on Nevro at Overweight

Financial news for NVRO dated on 2016-07-19: William Blair Initiates Coverage on Nevro at Outperform

Financial news for NVRO dated on 2016-07-12: Wells Fargo Initiates Coverage on Nevro at Outperform

Financial news for NVRO dated on 2016-06-14: Option Alert: NVRO Jun16 75.0 Puts: 1800 @ ASK \$4.20: 1800 traded vs 1861 OI: Earnings 8/4 \$71.94 Ref

Financial news for NVRO dated on 2016-06-08: Nevro Prices Public Offering of \$150M of 1.75% Convertible Senior Notes

Financial news for NVRO dated on 2016-05-09: Nevro Raises FY 2016 Revenue Guidance, Sees Revenue \$175M to \$185M vs \$165.97M est

Financial news for NVRO dated on 2016-05-09: Nervo Q1 EPS (\$0.33) vs (\$0.63) est, Revenue \$41.65M vs \$33.48M est

Financial news for NVRO dated on 2016-04-26: Nevro Has A Multi-Billion Dollar Opportunity

Financial news for NVRO dated on 2016-04-15: Nevro Reports FDA Approval of New Surgical Leads for Senza Spinal Cord Stimulation System Delivering HF10 Therapy

Financial news for NVRO dated on 2016-03-29: Northland Securities Initiates Coverage on Nevro at Market Perform, Announces \$48.00 PT

Financial news for NVRO dated on 2016-02-29: Nevro Announce CEO to Become Chairman of Board, Rami Elghandour to Become CEO

Financial news for NVRO dated on 2016-02-29: Nervo Raises FY 2016 Sales \$155M-\$165M Vs Est \$149.77M, Had Seen \$145M-\$155M

Financial news for NVRO dated on 2016-02-29: Nervo Reports Q4 EPS \$(0.51) Vs Est \$(0.56), Sales \$33.1M Vs Est \$32.88M, CEO To Transition To Role Of Exec. Chairman

Financial news for NVRO dated on 2016-02-05: Nevro Sells Off to Low of \$55 on Volume

Financial news for NVRO dated on 2016-01-11: Stocks Hitting 52-Week Highs

Financial news for NVRO dated on 2016-01-11: Nevro Sees FY2016 Sales \$145.0M-155.0M vs \$134.40M Est

Financial news for NVRO dated on 2016-01-11: Nevro Sees Q4 Sales \$32.60M-33.10M vs \$24.01M Est

Financial news for NVRO dated on 2016-01-04: Option Alert: NVRO Jan16 70.0 Calls Sweep: 1001 @ ASK \$1.54: 1001 traded vs 94 OI: \$65.73 Ref

Financial news for NVRO dated on 2015-12-14: J.P. Morgan Thinks Nevro Is About To Take Off, Sees Major Revenues Coming

Financial news for NVRO dated on 2015-12-14: Stocks Hitting 52-Week Highs

Financial news for NVRO dated on 2015-12-10: Nevro Announces CMS Approved Transitional Pass-through Payment for Outpatient Use of Co.'s Senza Spinal Cord Stimulation System

Financial news for NVRO dated on 2015-12-01: Nevro Announces USPTO Denies Boston Scientific Petitions for Inter Partes Review of U.S. Patent No. 8,359,102

Financial news for NVRO dated on 2015-11-30: Nevro Spikes to High of \$60.19

Financial news for NVRO dated on 2015-11-30: Shares of Nevro Jump \$0.70 Over Last Two Mins, Now Up ~0.5% for the Session

Financial news for NVRO dated on 2015-11-10: Benzinga's Volume Movers

Financial news for NVRO dated on 2015-11-09: Nevro Sees FY15 Sales \$59.5M-\$61.5M vs \$50.6M Est.

Financial news for NVRO dated on 2015-11-09: Nevro Reports Q3 EPS \$(0.70) vs \$(0.75) Est., Sales \$15.402M vs \$12.5M Est.

Financial news for NVRO dated on 2015-09-25: Benzinga's Top Initiations

Financial news for NVRO dated on 2015-09-25: BMO Capital Initiates Coverage on Nevro at Outperform, Announces \$65.00 PT

Financial news for NVRO dated on 2015-09-01: Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board

Financial news for NVRO dated on 2015-08-06: Nevro Reports Q2 EPS \$(0.77) vs. Est. \$(0.89), Rev. \$11.418M vs. Est. \$9.7M

Financial news for NVRO dated on 2015-06-18: Benzinga's Volume Movers

Financial news for NVRO dated on 2015-06-03: Nevro Prices Upsized ~4.705M Offering @\$51.00/Share

Financial news for NVRO dated on 2015-06-01: Nevro Announces Offering of ~1.476M Common Shares by Co., ~2.459M Shares by Selling Holders

Financial news for NVRO dated on 2015-05-18: S-1 from Nevro Corp. Shows Registration for \$200M Offering, \$75M via Co., \$125M via Selling Holders

Financial news for NVRO dated on 2015-05-12: Leerink Is Changing Targets At These 7 Biotechs

Financial news for NVRO dated on 2015-05-12: Nevro Announces Boston Scientific Unit Files Petitions for Inter Partes Review of U.S. Patent No. 8,359,102

Financial news for NVRO dated on 2015-05-11: Mid-Day Market Update: U.S. Stocks Mostly Lower; Rosetta Resources Shares Rise On Acquisition News

Financial news for NVRO dated on 2015-05-11: Benzinga's Volume Movers

Financial news for NVRO dated on 2015-05-11: Mid-Morning Market Update: Markets Edge Higher; Dean Foods Earnings Beat Views

Financial news for NVRO dated on 2015-05-11: Stocks Hitting 52-Week Highs

Financial news for NVRO dated on 2015-05-11: Morning Market Gainers

Financial news for NVRO dated on 2015-05-11: Nevro Reports Q1 EPS \$(0.57) vs. Est. \$(0.63), Rev. 9.662M vs. Est. \$8.53M

Financial news for NVRO dated on 2015-05-09: Nevro Receives FDA Approval for Senza Spinal Cord Stimulation System

Financial news for NVRO dated on 2015-03-19: Stocks Hitting 52-Week Highs

Financial news for NVRO dated on 2015-03-19: Morning Market Gainers

Financial news for NVRO dated on 2015-03-18: Nevro Reports Q4 EPS \$(0.59) vs. Est. \$(0.54), Rev. \$9.7M vs. Est. \$8.4M

Financial news for NVRO dated on 2015-03-10: CRT Capital Initiates Coverage on Nevro at Buy

Financial news for NVRO dated on 2015-03-09: CRT Capital Initiates Coverage on Nevro at Buy, Announces \$55.00 PT

Financial news for NVRO dated on 2015-01-23: Why Nevro Is Trading 25% Higher

Financial news for NVRO dated on 2015-01-23: Stocks Hitting 52-Week Highs

Financial news for NVRO dated on 2015-01-23: Morning Market Gainers

Financial news for NVRO dated on 2015-01-22: Nevro Receives Approvable Letter from FDA for Senza Spinal Cord Stimulation System

Financial news for NVRO dated on 2014-12-03: UPDATE: Morgan Stanley Reiterates On Nevro On Improving Margins

Financial news for NVRO dated on 2014-11-06: Shares of Nevro Open for Trade at \$23.40/Share, IPO Priced at \$18

Financial news for NVRO dated on 2014-11-06: Expected IPOs For November 6

Financial news for NVRO dated on 2014-11-06: Nevro Prices 7M Share IPO @\$18.00/Share

Financial news for NVRO dated on 2014-10-27: Nevro Corp. Expects 6.25M Share IPO to Price \$15.00-\$17.00/Share